Name: The strong outlook with revenue visibility stretching well into 2024, and what’s behind the upgrade of sales and profit outlook, and introduction of a new regular dividend.
Uploaded: 2023-09-12T08:51:00.633492+00:00
Duration: 712 s
Channel: Vox Markets
Description: The strong outlook with revenue visibility stretching well into 2024, and what’s behind the upgrade of sales and profit outlook, and introduction of a new regular dividend.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/006/318/006318/video_OcOIn4a.mp4#t=592

Vox Markets

The strong outlook with revenue visibility stretching well into 2024, and what’s behind the upgrade of sales and profit outlook, and introduction of a new regular dividend.

Mo Khan discusses the highlights of the strong half-year results.

How the diversification of the business across new challenge models and the expansion of the scope of its services is underpinning scalable growth.

Real world examples of how human challenge models are accelerating the drug delivery process at large biopharma companies.

The success in scaling up the business, including recent news of a new facility to conduct human challenge trials to be opened

How a focus on operational efficiency is driving margin expansion, and the impact of the new facility

hVIVO’s Mo Khan: “we are seeing revenue fully contracted well into next year”

Mo Khan, chief executive of hVIVO, talks to Vox Markets about what’s behind the company’s blockbuster half-year results and an upgrade of its full year sales and profit forecasts, and the commitment to a new regular dividend. 

In this interview, hVIVO chief executive Mo Khan talks to Vox about what’s behind the company’s blockbuster half-year results and an upgrade of its full year sales and profit forecasts, including the development of new human challenge models and a continued focus on driving operational efficiency, underpinned by a move to a new state-of-the-art facility.

0:37 Mo Khan discusses the highlights of the strong half-year results.

2:08 How the diversification of the business across new challenge models and the expansion of the scope of its services is underpinning scalable growth.

4:20 Real world examples of how human challenge models are accelerating the drug delivery process at large biopharma companies.

7:10 The success in scaling up the business, including recent news of a new facility to conduct human challenge trials to be opened 

9:09 How a focus on operational efficiency is driving margin expansion, and the impact of the new facility 

9:52 The strong outlook with revenue visibility stretching well into 2024, and what’s behind the upgrade of sales and profit outlook, and introduction of a new regular dividend.

hVIVO’s Mo Khan: “we are seeing revenue fully contracted well into next year”Mo Khan, chief executive of hVIVO, talks to Vox Markets about what’s behind the company’s blockbuster half-year results and an upgrade of its full year sales and profit forecasts, and the commitment to a new regular dividend. In this interview, hVIVO chief executive Mo Khan talks to Vox about what’s behind the company’s blockbuster half-year results and an upgrade of its full year sales and profit forecasts, including the development of new human challenge models and a continued focus on driving operational efficiency, underpinned by a move to a new state-of-the-art facility.0:37 Mo Khan discusses the highlights of the strong half-year results.2:08 How the diversification of the business across new challenge models and the expansion of the scope of its services is underpinning scalable growth.4:20 Real world examples of how human challenge models are accelerating the drug delivery process at large biopharma companies.7:10 The success in scaling up the business, including recent news of a new facility to conduct human challenge trials to be opened 9:09 How a focus on operational efficiency is driving margin expansion, and the impact of the new facility 9:52 The strong outlook with revenue visibility stretching well into 2024, and what’s behind the upgrade of sales and profit outlook, and introduction of a new regular dividend.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/006/318/006318/video_OcOIn4a.mp4